Publication | Open Access

Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): post-progression outcomes and updated safety results from a randomised, placebo-controlled, phase 3 trial

Post-progression OutcomesMedicineMetronomic TherapyRecurrent Ovarian CarcinomaGynecologyCancer TreatmentUpdated Safety ResultsOncologyRadiation OncologyGynecology OncologyOvarian Cancer